Positron to Exhibit at Radiological Society of North America's Annual Conference
23 Novembre 2010 - 2:00PM
Positron Corporation (OTCBB:POSC), a molecular imaging solutions
company focused on Nuclear Cardiology, will attend the 96th
Scientific Assembly and Annual Meeting (RSNA) in Chicago, Illinois,
being held November 28th to December 3rd , 2010.
RSNA is an association of more than 44,000 radiologists,
radiation oncologists, medical physicists and related scientists
committed to excellence in patient care through education and
research. This year's conference will feature over 2,400 scientific
presentations and posters covering the newest trends in
radiological research, and more than 1,900 education and
informatics exhibits. Attendees will have the opportunity to
interview experts in all radiologic subspecialties and related
fields.
Joseph Oliverio, chief technology officer of Positron states,
"The RSNA Annual Meeting is the biggest and most prestigious forum
hosting the latest most cutting-edge information in radiology and
medical imaging of any meeting, anywhere in the world. It's an
ideal fit for Positron to exhibit its unique and relevant position
in the nuclear medicine community."
The Company is anticipating a high level of interest in its
Attrius® cardiac specific PET scanner and, more specific to this
radiology-based conference, its Nuclear Pharm-Assist®, an FDG
automated compounding, handling and shielding device and
Tech-Assist™, an FDG dose administration and shielding system.
The mission of the RSNA meeting is to promote and develop the
highest standards of radiology and related sciences through
education and research to advance the quality of healthcare
provided. For further information please visit the RSNA
website at www.rsna.org.
About Positron: Positron is a molecular imaging
company focused on Nuclear Cardiology. Positron utilizes its
proprietary product line to provide unique solutions to the Nuclear
Medicine community ranging from imaging to radiopharmaceutical
distribution. Positron products include: the Attrius®, a PET
imaging device; the Pulse®, a SPECT imaging device; the Nuclear
Pharm-Assist®, an automated radiopharmaceutical distribution
device; and the Tech-Assist™, a radiopharmaceutical injection
shield. More information about Positron is available at
www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended.
These statements are based on many assumptions and estimates and
are not guarantees of future performance and may involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Positron Corporation
to be materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
CONTACT: Positron Corporation
(317)576-0183
Grafico Azioni Positron (PK) (USOTC:POSC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Positron (PK) (USOTC:POSC)
Storico
Da Dic 2023 a Dic 2024